MX377118B - C. novyi para el tratamiento de tumores solidos en humanos. - Google Patents

C. novyi para el tratamiento de tumores solidos en humanos.

Info

Publication number
MX377118B
MX377118B MX2015013784A MX2015013784A MX377118B MX 377118 B MX377118 B MX 377118B MX 2015013784 A MX2015013784 A MX 2015013784A MX 2015013784 A MX2015013784 A MX 2015013784A MX 377118 B MX377118 B MX 377118B
Authority
MX
Mexico
Prior art keywords
human
novyi
methods
solid tumor
sup
Prior art date
Application number
MX2015013784A
Other languages
English (en)
Spanish (es)
Other versions
MX2015013784A (es
Inventor
Bert Vogelstein
Kenneth W Kinzler
Saurabh Saha
Shibin Zhou
Original Assignee
Biomed Valley Discoveries Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries Inc, Univ Johns Hopkins filed Critical Biomed Valley Discoveries Inc
Publication of MX2015013784A publication Critical patent/MX2015013784A/es
Publication of MX377118B publication Critical patent/MX377118B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/742Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
MX2015013784A 2013-03-29 2014-03-28 C. novyi para el tratamiento de tumores solidos en humanos. MX377118B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361806497P 2013-03-29 2013-03-29
PCT/US2014/032196 WO2014160950A1 (en) 2013-03-29 2014-03-28 C. novyi for the treatment of solid tumors in humans

Publications (2)

Publication Number Publication Date
MX2015013784A MX2015013784A (es) 2016-08-08
MX377118B true MX377118B (es) 2025-03-07

Family

ID=51625539

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013784A MX377118B (es) 2013-03-29 2014-03-28 C. novyi para el tratamiento de tumores solidos en humanos.

Country Status (20)

Country Link
US (3) US10617723B2 (enExample)
EP (4) EP4108248B1 (enExample)
JP (6) JP6756609B2 (enExample)
KR (1) KR20160021084A (enExample)
CN (2) CN116570628A (enExample)
AU (2) AU2014240872A1 (enExample)
BR (2) BR112015024621B1 (enExample)
CA (2) CA2908508C (enExample)
DK (1) DK2988760T3 (enExample)
ES (3) ES2815564T3 (enExample)
HK (1) HK1222134A1 (enExample)
IL (1) IL241823B (enExample)
MX (1) MX377118B (enExample)
NZ (1) NZ712691A (enExample)
PH (1) PH12015502260B1 (enExample)
RU (1) RU2718670C2 (enExample)
SG (2) SG11201508071VA (enExample)
UA (1) UA120036C2 (enExample)
WO (1) WO2014160950A1 (enExample)
ZA (2) ZA201507412B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015240884B2 (en) * 2014-03-31 2020-06-18 Biomed Valley Discoveries, Inc. Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
CN105912930B (zh) * 2016-04-11 2019-02-01 北京奇虎科技有限公司 移动终端及其系统资源安全控制方法
WO2018039185A1 (en) * 2016-08-23 2018-03-01 Mayo Foundation For Medical Education And Research Methods and materials for treating estrogen receptor positive breast cancer
CN110799245B (zh) * 2017-05-16 2022-08-09 生物医学谷探索股份有限公司 用于治疗具有非典型braf突变的癌症的组合物和方法
CN109985039A (zh) * 2017-12-29 2019-07-09 深圳微芯生物科技股份有限公司 用于治疗白血病的联合用药物及其在制备用于治疗急性髓性白血病的药物中的用途
WO2021231611A1 (en) * 2020-05-12 2021-11-18 Splash Pharmaceuticals, Inc. Methods for treating cancer using spl-108 polypeptide based on tp53 mutational status
US11717787B2 (en) 2021-01-04 2023-08-08 Saudi Arabian Oil Company High free volume membrane for gas separation
CN116917009A (zh) 2021-02-19 2023-10-20 美国迈胜医疗系统有限公司 用于粒子治疗系统的机架
CN113855710B (zh) * 2021-10-09 2024-02-20 施慧达药业集团(吉林)有限公司 戈氏梭菌联合肿瘤血管生成抑制剂的应用
CN115350145A (zh) * 2022-09-06 2022-11-18 华中科技大学同济医学院附属协和医院 细菌介导负载二甲双胍的多肽水凝胶在肿瘤免疫治疗中的应用
WO2025163852A1 (ja) * 2024-02-01 2025-08-07 ミヤリサン製薬株式会社 Cd4-cd8-t細胞を増殖および/または活性化させるための組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599331A (en) 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
EP0245357B1 (en) 1985-10-23 1991-08-07 The Upjohn Company Angiostatic steroids
US4771042A (en) 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
EP0477195A1 (en) 1989-06-16 1992-04-01 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis
AU678961B2 (en) 1991-11-22 1997-06-19 Alcon Laboratories, Inc. Angiostatic steroids
WO2002067796A1 (en) 2001-02-28 2002-09-06 Rex Medical, L.P. Apparatus for delivering ablation fluid to treat neoplasms
DK1446012T3 (da) 2001-11-21 2013-10-14 Univ Johns Hopkins Bakteriolytisk kombinationsterapi til behandling af tumorer
WO2005018332A1 (en) * 2003-08-13 2005-03-03 The General Hospital Corporation Modified microorganisms for anti-cancer therapy
ATE459364T1 (de) 2003-10-22 2010-03-15 Univ Johns Hopkins Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
US20070015738A1 (en) * 2005-07-15 2007-01-18 Walker Stephen G Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid

Also Published As

Publication number Publication date
JP7788114B2 (ja) 2025-12-18
JP2020152734A (ja) 2020-09-24
KR20160021084A (ko) 2016-02-24
ES2922378T3 (es) 2022-09-14
EP3730146B1 (en) 2022-05-04
EP2988760B1 (en) 2020-06-17
JP6756609B2 (ja) 2020-09-16
SG11201508071VA (en) 2015-10-29
CN105451750B (zh) 2023-03-10
US20160051597A1 (en) 2016-02-25
JP2019011376A (ja) 2019-01-24
JP2022022392A (ja) 2022-02-03
ZA201706402B (en) 2019-01-30
PH12015502260A1 (en) 2016-02-01
US20200330525A1 (en) 2020-10-22
JP7445893B2 (ja) 2024-03-08
ES2815564T3 (es) 2021-03-30
JP2024056012A (ja) 2024-04-19
CA2908508C (en) 2023-09-19
SG10201902765VA (en) 2019-04-29
UA120036C2 (uk) 2019-09-25
CN105451750A (zh) 2016-03-30
AU2014240872A1 (en) 2015-10-22
RU2020111670A (ru) 2020-04-13
MX2015013784A (es) 2016-08-08
EP4653054A2 (en) 2025-11-26
US11439669B2 (en) 2022-09-13
RU2718670C2 (ru) 2020-04-13
JP2016515586A (ja) 2016-05-30
ZA201507412B (en) 2018-05-30
CA3206655A1 (en) 2014-10-02
WO2014160950A1 (en) 2014-10-02
DK2988760T3 (da) 2020-07-13
BR122020006408B1 (pt) 2021-09-28
HK1222134A1 (zh) 2017-06-23
CA2908508A1 (en) 2014-10-02
BR112015024621B1 (pt) 2021-09-28
JP2017088619A (ja) 2017-05-25
AU2019200276B2 (en) 2020-06-11
EP2988760A4 (en) 2016-10-05
PH12015502260B1 (en) 2022-11-16
NZ712691A (en) 2020-01-31
EP4108248B1 (en) 2025-09-17
RU2015146199A (ru) 2017-05-10
EP3730146A1 (en) 2020-10-28
CN116570628A (zh) 2023-08-11
IL241823B (en) 2021-02-28
ES3048113T3 (en) 2025-12-09
EP2988760A1 (en) 2016-03-02
AU2019200276A1 (en) 2019-02-07
US10617723B2 (en) 2020-04-14
US20220378852A1 (en) 2022-12-01
EP4108248A1 (en) 2022-12-28
BR112015024621A8 (pt) 2019-12-10
BR112015024621A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
MX377118B (es) C. novyi para el tratamiento de tumores solidos en humanos.
CY1123258T1 (el) Μεθοδος θεραπειας για τον καρκινο
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
SG10201902664RA (en) Combination therapy for treating cancer
BR112018008503A2 (pt) método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer
WO2016025635A3 (en) Combination therapy for treating cancer
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
MX2020003959A (es) Metodos terapeuticos relacionados con los inhibidores de hsp90.
NZ700759A (en) Combination therapy for treating cancer
MX384403B (es) Terapia de combinación para el tratamiento del cáncer.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
MX2018002344A (es) Metodo para tratar el cancer.
WO2016043874A3 (en) Combination therapy for treating cancer
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
BR112017000556A2 (pt) terapia de combinação para câncer
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020001727A (es) Terapia de combinacion.
CR11631A (es) Paramyxovirus eficaz como antitumoral
JOP20200242A1 (ar) مركبات البلاديينوليد واستخداماتها
WO2014160967A8 (en) C. novyi for the treatment of solid tumors in non-human animals
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.

Legal Events

Date Code Title Description
FG Grant or registration